Although there is much evidence to substantiate the view that tumor necrosis factor (TNF) plays a pivotal role in the pathogenesis of multiple organ injury subsequent to intestinal ischemia/reperfusion (I/R), it is still unclear whether TNF is involved in triggering the release of other inflammatory mediators in this condition. The current study was designed to determine the potential effects of TNF blockade, by means of monoclonal antibody (TNF MoAb) treatment, on plasma interleukin 6 (IL-6) in rats after acute intestinal I/R injury. Anesthetized rats underwent 75-min occlusion of superior mesenteric artery followed by 6 hr of reperfusion. The animals were treated with TNF MoAb or control protein at a dose of 20 mg/kg i.v. 30 min before the onset of I/R. Similar IL-6 responses in both the portal and the systemic circulation were observed in animals subjected to intestinal I/R, who showed a progressive increase in plasma IL-6 concentration upon release of the clamp. In animals receiving TNF MoAb before I/R, the subsequent IL-6 release following reperfusion was significantly blunted compared to the levels in controls (P < 0.05). The present study demonstrates that the activation and/or release of IL-6 in the setting of acute gut I/R may, at least in part, be mediated via TNF-dependent mechanisms, providing further evidence that a complex interaction exists between TNF and IL-6.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1006/jsre.1997.5074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease.
Front Immunol
September 2021
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Daratumumab is a monoclonal antibody directed against the transmembrane glycoprotein CD38 expressed on plasma cells and lymphoplasmocytes, with a proven efficacy in multiple myeloma. Here we show its clinical efficacy in a patient with cold agglutinin disease (CAD) relapsed after multiple lines of therapy. CAD is caused by cold reactive autoantibodies that induce complement mediated hemolysis and peripheral circulatory symptoms.
View Article and Find Full Text PDFTailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Semin Arthritis Rheum
April 2016
Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS. Rome, Italy.
Objective: A multidisciplinary expert panel, the Italian board for the TAilored BIOlogic therapy (ITABIO), was constituted to formulate evidence-based decisional statements for the first-line tailored biologic therapy in patient with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA).
Methods: Systematic review of the literature to identify English-language articles on the variables influencing the first-line biologic choice, including the efficacy and safety of the drug, the route of administration, the availability of response predictor biomarkers, the need of monotherapy, the patient socio-economic status, lifestyle, cultural level, personality, fertility and childbearing potential in women, the presence of comorbidities, the host-related risk factors for infection and latent tuberculosis infection (LTBI) reactivation, the cardiovascular (CV) risk, and costs.
Results: Some variables, including the patients' preference, the indication for anti-TNF monotherapy in potential childbearing women, and the intravenous route with dose titration in obese subjects resulted valid for all the three rheumatic conditions.
CD5L (CD5 molecule-like) is a secreted glycoprotein that participates in host response to bacterial infection. CD5L influences the monocyte inflammatory response to the bacterial surface molecules lipopolysaccharide (LPS) and lipoteichoic acid (LTA) by inhibiting TNF secretion. Here we studied the intracellular events that lead to macrophage TNF inhibition by human CD5L.
View Article and Find Full Text PDFEnteropathogenic Escherichia coli (EPEC) binding to human intestinal cells triggers the formation of disease-associated actin rich structures called pedestals. The latter process requires the delivery, via a Type 3 secretion system, of the translocated Intimin receptor (Tir) protein into the host plasma membrane where binding of a host kinase-modified form to the bacterial surface protein Intimin triggers pedestal formation. Tir-Intimin interaction recruits the Nck adaptor to a Tir tyrosine phosphorylated residue where it activates neural Wiskott-Aldrich syndrome protein (N-WASP); initiating the major pathway to actin polymerization mediated by the actin-related protein (Arp) 2/3 complex.
View Article and Find Full Text PDFLeptin upregulates tissue factor expression in human breast cancer MCF-7 cells.
Thromb Res
May 2012
Research Laboratories, Giovanni Paolo II Center for High Technology Research, and Education in Biomedical Sciences, Catholic University, Largo Gemelli 1, 86100 Campobasso, Italy.
Introduction: Obesity is a risk factor for both cardiovascular disease and cancer development. Leptin, a cytokine produced by adipose tissue, controls different processes in peripheral tissues, including cancer development and thrombotic disorders in patients with a variety of clinical disorders. Tissue factor (TF), the trigger of blood clotting, is abundant in the adipose tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!